Phosphodiesterases (PDEs) regulate the local concentration of 3,5 cyclic adenosine monophosphate (cAMP) within cells. cAMP activates the cAMP-dependent protein kinase (PKA). In patients, PDE inhibitors have been linked to heart failure and cardiac arrhythmias, although the mechanisms are not understood. We show that PDE4D gene inactivation in mice results in a progressive cardiomyopathy, accelerated heart failure after myocardial infarction, and cardiac arrhythmias. The phosphodiesterase 4D3 (PDE4D3) was found in the cardiac ryanodine receptor (RyR2)/ calcium-release-channel complex (required for excitation-contraction [EC] coupling in heart muscle). PDE4D3 levels in the RyR2 complex were reduced in failing human hearts, contributing to PKA-hyperphosphorylated, "leaky" RyR2 channels that promote cardiac dysfunction and arrhythmias. Cardiac arrhythmias and dysfunction associated with PDE4 inhibition or deficiency were suppressed in mice harboring RyR2 that cannot be PKA phosphorylated. These data suggest that reduced PDE4D activity causes defective RyR2-channel function associated with heart failure and arrhythmias.
Introduction
Phosphodiesterases (PDEs) control the temporal and spatial dynamics of the second messenger 3#,5# cyclic adenosine monophosphate (cAMP), allowing for highly localized cAMP gradients in cells (Zaccolo and Pozzan, 2002) . Localization of PDEs in close proximity to cAMPdependent protein kinase A (PKA) is thought to control access of cAMP to the regulatory kinase subunit (Conti et al., 2003; Houslay and Adams, 2003) . PKA phosphor-*Correspondence: arm42@columbia.edu 5 These authors contributed equally to this work. ylation of proteins mediates a wide variety of signals, including those generated during activation of the sympathetic nervous system (SNS) as part of the "fight or flight" response. On the other hand, chronic activation of the SNS is a characteristic finding in heart failure, and acute stimulation of the SNS has been linked to triggered arrhythmias associated with sudden cardiac death.
In the heart, phosphodiesterase 4 (PDE4) contributes to the regulation of cAMP levels in cardiac myocytes. In particular, PDE4 cAMP-hydrolyzing activity has been localized to the transverse (T) tubule/sarcoplasmic reticulum (SR) junctional space that is involved in excitation-contraction coupling ( The PDE superfamily is subgrouped into 11 families that include at least 20 genes and 50 unique isoforms. Of these PDE families, only PDE4, PDE7, and PDE8 are cAMP specific (Conti et al., 2003) . Through alternative splicing and the use of multiple promotors, the PDE4D gene encodes nine variants (PDE4D1-9) with identical catalytic domains and carboxyl termini and unique amino termini important for subcellular localization. PKA-PDE signaling has been identified as a therapeutic target in several major diseases (Conti et al., 2003) . Inhibitors of the PDE4 family are under development for asthma, chronic obstructive lung disease (COPD), cognitive disorders including Alzheimer's disease, and stroke (Gong et al., 2004; Gretarsdottir et al., 2003; Vignola, 2004) . However, nonspecific PDE inhibition with theophylline, commonly used to treat asthma and COPD, and trials using PDE3 inhibition to treat heart failure have demonstrated increased mortality due to cardiac arrhythmias (Barnes, 2003; Packer et al., 1991) .
We now show that PDE4D deficiency in mice is associated with a cardiac phenotype comprised of a progressive, age-related cardiomyopathy and exercise-induced arrhythmias, despite normal global cAMP signaling. Furthermore, PDE4D3 was found to be an integral component of the RyR2 macromolecular signaling complex. RyR2 located on the sarcoplasmic reticulum (SR) is the major Ca 2+ -release channel required for excitation-contraction coupling in heart muscle. RyR2 channels were PKA hyperphosphorylated and exhibited a "leaky" phenotype in PDE4D-deficient mice, similar to RyR2 defects observed in patients with heart failure and sudden cardiac death (SCD) (Marx et al., 2000; Wehrens et al., 2003) . In failing human hearts, PDE4D3 levels were reduced in the RyR2 complex. Moreover, mice with PDE4D deficiency exhibited accelerated progression of heart failure following myocardial infarction associated with RyR2 channels that were PKA hyperphosphorylated and exhibited a "leaky" phenotype. Pharmacological PDE4 inhibition was associated with exerciseinduced cardiac arrhythmias that were suppressed in mice harboring a mutation that prevents PKA phosphorylation of the RyR2 channel. Our data suggest that PDE4D deficiency may contribute to heart failure and arrhythmias by promoting defective regulation of the RyR2 channel.
Results

PDE4D Gene Inactivation Causes Age-Related Cardiomyopathy
To explore the consequences of chronic PDE4D deficiency on cardiac function, we used a mouse model of PDE4D gene inactivation (Jin et al., 1999) . Echocardiography of PDE4D −/− mice showed a progressive, agedependent increase in left ventricular end-diastolic diameter (LVEDD), a hallmark of cardiac dysfunction (Figure 1A ; n = 12 each for wild-type [wt] and PDE4D −/− ). PDE4D −/− mice exhibited increased heart-weight-tobody-weight (HW/BW) ratios compared to wt controls ( Figure 1B) . PDE4D −/− mice had reduced ejection fractions (EF) and cardiac contractility (dP/dt)/P id , documented by cardiac catheterization (Figures 1C and 1D ). Histologic examination of PDE4D −/− hearts confirmed that the 15-month-old hearts were dilated, with no other structural abnormalities ( Figure 1E ). These data show that PDE4D deficiency is associated with progressive cardiac dysfunction consistent with a dilated cardiomyopathy similar to that seen in patients with chronic heart failure.
Global cAMP Signaling Is Normal in PDE4D-Deficient Mice
It is well established that chronic hyperadrenergic signaling is associated with heart failure. Therefore, we sought to determine whether the mechanism underlying the observed cardiac phenotype in PDE4D −/− mice was increased global cAMP signaling. However, there were no significant differences in global cAMP levels and β-adrenergic receptors in hearts from PDE4D −/− mice (Figures 2A-2C) . Total cAMP-hydrolyzing activity of PDE in the heart was only slightly decreased in PDE4D −/− mice (data not shown), consistent with PDE4D activity representing only a fraction of total cytosolic PDE cAMP-hydrolyzing activity in the heart (Mongillo et al., 2004; Richter et al., 2005) . However, rolipram-sensitive PDE4 activity in PDE4D −/− heart was reduced by w50% (data not shown). Whereas global cAMP signaling was not perturbed in PDE4D-deficient mice, there was a significant increase in localized cAMP levels at the cardiomyocyte Z line (correspond- ing to the location of the RyR2 channel) in cardiomyocytes isolated from PDE4D −/− mice following a low dose (1 nM) of isoproterenol ( Figures 2D and 2E) . Thus, the abnormalities observed in cardiac function of PDE4D −/− mice must be explained by defects in localized cAMPdependent signaling.
PKA Phosphorylation of RyR2 in PDE4D
−/− Mice While many proteins in the heart are regulated by PKA phosphorylation and therefore can be affected by al- Given that RyR2 PKA hyperphosphorylation has been linked to cardiac dysfunction in humans and animal models and that cAMP concentrations are increased in the compartment of RyR2 Ca 2+ release ( Figures 2D and  2E) , we sought to determine whether RyR2 PKA hyperphosphorylation might play a role in the observed cardiac phenotype in PDE4D −/− mice. Indeed, there was a progressive, age-dependent increase in PKA phosphorylation of RyR2 on Ser2808 (detected using a phosphoepitope-specific antibody) in PDE4D −/− mouse hearts ( Figures 3A and 3B) . PKA hyperphosphorylation of RyR2 in PDE4D −/− mouse hearts was associated with depletion of the RyR2-stabilizing protein calstabin2 (FKBP12.6) that prevents Ca 2+ leak from the SR into the cytosol through RyR2 during diastole in the heart (Figure 3C) Figure 3A) . Moreover, no changes in PP1 or PP2A phosphatase levels in the RyR2-complex levels were detected (data not shown). Phosphorylation of RyR2 by another kinase that phosphorylates the channel, Ca 2+ /calmodulindependent protein kinase A (CaMKII) (detected using a phosphoepitope-specific antibody), was not altered in PDE4D −/− mouse hearts ( Figures 3A and 3D ). In wt mice, PDE activity was associated with immunoprecipitated RyR2 channels ( Figure 3E ). RyR2-associated PDE activity was almost completely inhibited by the PDE4 antagonist rolipram but not by the PDE3 inhibitor milrinone. Moreover, PDE activity specifically associated with RyR2 channels was reduced to zero in the PDE4D −/− mice ( Figure 3E ). Taken together, these data suggested that one consequence of PDE4D deficiency is PKA hyperphosphorylation of RyR2, which has previously been associated with heart failure (Marx et al., 2000) . Moreover, it appeared that the PDE activity associated with the RyR2 complex was encoded by the PDE4D gene. 
Abnormal RyR2 Channels in PDE4D-Deficient Hearts
PDE4D3 Is a Component of the RyR2 Macromolecular Complex
The finding that the PDE activity that coimmunoprecipitates with RyR2 was abrogated in channels from . We generated an isoform-specific antibody against the unique N-terminal epitope of PDE4D3 ( Figure 4A ). PDE4D splice variants were identified by RT-PCR in heart (data not shown), and PDE4D3, PDE4D8, and PDE4D9 expression in the heart was demonstrated using isoform-specific antibodies ( Figure  4B ), confirming that these are the major PDE4D isoforms expressed in heart muscle (Richter et al., 2005) .
To examine the possibility that a specific PDE4D isoform is part of the cardiac RyR2 channel complex, immunoprecipitations were performed using human heart extracts. RyR2 channels were immunoprecipitated with anti-RyR2 antibody and assayed for coimmunoprecipitation of PDE4D3, PDE4D8, or PDE4D9 with RyR2 by immunoblotting. Using isoform-specific PDE4D antibodies, only PDE4D3 was detected in the RyR2 complex. In addition, anti-PDE4D3 antibody was used to coimmunoprecipitate RyR2 ( Figure 4B ). The interaction between PDE4D3 and RyR2 was specific because PDE4D3 was excluded from immunoprecipitates using control IgG ( Figure 4B ). Moreover, we used the PDE4D3-specific antibody to show that total PDE4D3 protein was decreased w37% in haploinsufficient PDE4D +/− mouse hearts and by 100% in homozygous PDE4D −/− hearts ( Figure 4C ). Finally, PDE4D3 in the RyR2 macromolecular signaling complex was also decreased by w44% in PDE4D +/− mouse hearts and by 100% in PDE4D −/− heart ( Figure 4D ). Taken together, these data show that PDE4D3 is an integral component of the RyR2 macromolecular complex in the heart and that PDE4D3 is the only PDE isoform in the RyR2 complex.
PDE4D3 Is Decreased in the RyR2
Complex in Failing Human Hearts PDE4D3 was also associated with RyR2 from human hearts ( Figure 5A ). In human heart failure (HF), PDE4D3 ., 2003a) . The cAMP-hydrolyzing activity of RyR2 bound PDE4D3 was decreased by 42% in human HF samples (n = 6, each experiment was performed in triplicate; p < 0.001), providing a possible explanation for chronic RyR2-Ser2808 PKA hyperphosphorylation observed in failing human hearts ( Figure 5C ). This reduction in PDE4D3 activity in the human HF RyR2 complex was comparable to that observed in the RyR2 complexes in PDE4D +/− mice ( Figure 4D ). To explore the basis for the observed reduction in PDE4D3 amount and activity in the HF RyR2 complex, we examined PKA phosphorylation of PDE4D3, which has been shown to increase its activity (Sette and Conti, 1996) PDE4-specific inhibition with rolipram (10 M) significantly decreased RyR2 bound PDE4D3 activity in normal human heart lysates (n = 3, p < 0.01), whereas the PDE3-specific inhibitor milrinone (10 M) had no effect on RyR2-associated PDE activity ( Figure 5D ), confirming that the cAMP-hydrolyzing activity in the RyR2 complex is due to PDE4. Thus, PDE4D3 is part of the human RyR2 signaling complex, and reduction of PDE4D3 activity in heart failure may contribute to RyR2 PKA hyperphosphorylation and diastolic SR Ca 2+ leak observed in failing hearts (Shannon et al., 2003) .
Cardiac Arrhythmias due to PDE4 Inhibition Are Suppressed in Mice Harboring RyR2 that Cannot be PKA Phosphorylated
We have previously demonstrated a link between PKA hyperphosphorylation of RyR2, "leaky" RyR2 channels, and exercise-induced sudden cardiac death (Wehrens et al., 2003) . Therefore, in the present study, we sought to determine whether PDE4D-deficient mice, which exhibit PKA-hyperphosphorylated RyR2, are more susceptible to exercise-induced cardiac arrhythmias. Resting heart rate in PDE4D −/− mice at 3-4 months of age was similar to wt, consistent with unchanged baseline sympathetic activity (wt 584 ± 22 bpm, PDE4D −/− 603 ± 32 bpm; p = NS). Since PDE inhibitors increase arrhythmogenic sudden cardiac death ( Figure 6C ). Importantly, RyR2-S2808A knockin mice, which express a mutant RyR2 that cannot be PKA phosphorylated (Figure 6B) , were protected against rolipram-induced exercise-triggered arrhythmias ( Figure 6C ). These findings indicate that the proarrhythmogenic effects of PDE4 inhibition are specifically due to PKA hyperphosphorylation of RyR2 at Ser2808. Thus, PKA phosphorylation of RyR2 at Ser2808 is necessary in order to generate triggered cardiac arrhythmias associated with PDE4 inhibition. Moreover, mortality due to sudden cardiac death at 24 and 72 hr following myocardial infarction (MI, induced by ligation of the left anterior descending artery) was significantly increased in PDE4D +/− compared to wt mice ( Figure 6D ), further suggesting that PDE deficiency in the RyR2-channel complex increases susceptibility to cardiac arrhythmias.
Exacerbation of Acute Heart Failure Associated with PDE4D3 Deficiency Is Attenuated in Mice Harboring
RyR2 that Cannot be PKA Phosphorylated Since PDE4D3 protein levels and cAMP-hydrolyzing activity in the RyR2 complex were reduced by 42% and 43% in human heart failure, respectively, we examined whether a partial reduction of PDE4D in haploinsufficient PDE4D +/− mice affects progression of HF. Heterozygous PDE4D +/− and wt control mice were subjected to proximal left anterior descending (LAD) coronary artery ligation to induce myocardial infarction (MI), which results in progressive heart failure. Similar to human heart failure ( Figure 5B ), PDE4D +/− mice had a 44% reduction of PDE4D3 bound to the RyR2 complex as compared to control ( Figure 4D ) and developed significantly worse heart failure manifested by a larger increase in cardiac dimensions and more depressed cardiac contractility over a 28 day post-MI period (Figure 7) . Cardiac dimensions (LVEDD) were 30% larger in PDE4D +/− hearts compared to wt 28 days post-MI (Figure 7A) , consistent with more severe cardiomyopathy. Infarct sizes were not significantly different in 4-to 5-month-old wt (35.8% ± 3.1% LV, n = 11) and PDE4D +/− mice (37.2% ± 3.7% LV, n = 14). Cardiac function, measured by echocardiography and cardiac catheterization, was reduced in haploinsufficient PDE4D +/− mice compared with wt mice following MI (Figures 7B and  7C) . Accelerated HF progression in PDE4D +/− mice was associated with enhanced RyR2 PKA hyperphosphorylation and reduced PDE4D3 protein levels in the RyR2 complex ( Figures 7D and 7E ) and significantly reduced PDE4D3 enzymatic activity in the RyR2 complex ( Figure  7F ). In the RyR2 complex, PKA catalytic and regulatory subunits, as well as the levels of the protein phosphatases PP1 and PP2A, were not significantly different between wt and PDE4D +/− hearts (data not shown). Thus, reduction of PDE4D3 activity in the RyR2 complex in haploinsufficient PDE4D +/− mice to levels similar to those observed in RyR2 complexes from failing human hearts results in accelerated progression of heart failure.
We next set out to determine whether the detrimental effects of PDE4D deficiency in the heart were dependent on dysfunction of the RyR2-channel complex due to PKA hyperphosphorylation and reduced binding of calstabin2. Since recent studies have demonstrated that the 1,4-benzothiazepine JTV-519 increases the binding of calstabin2 to RyR2 in vivo, we treated PDE4D +/− mice subjected to myocardial infarction with JTV-519. Treatment with JTV-519 (symbols) significantly increased the amount of calstabin2 bound to RyR2 ( Figure 7D ) and was associated with improved cardiac function following MI (Figures 7B and 7C) . We also crossed the PDE4D +/− mice with RyR2-S2808A mice to investigate the specific role of PKA hyperphosphorylation of RyR2 in the development of cardiac dysfunction in PDE4D +/− mice. RyR2-S2808A mice harbor RyR2 that cannot be PKA phosphorylated ( Figure 7D ). Prevention of PKA hyperphosphorylation improved cardiac function in PDE4D +/− mice subjected to MI ( Figures 7A  and 7C, green line and bars) . Infarct sizes were not significantly different between PDE4D +/− mice, PDE4D +/− mice treated with JTV-519 (38.6% ± 3.9% LV, n = 12), or PDE4D +/− mice crossed with RyR2-S2808A mice (39.8% ± 4.3% LV, n = 11). These data demonstrate that normalizing RyR2 function, either by enhancing calstabin2 binding to RyR2 or by preventing PKA hyperphosphorylation of RyR2, improved cardiac function in PDE4D +/− mice following myocardial infarction. Taken together, these data suggest that the cardiac defects observed in PDE4D-deficient mice are due, at least in part, to defective RyR2 function.
Discussion
The present study shows that phosphodiesterase (PDE4D) deficiency is associated with a severe cardiac phenotype consisting of heart failure and lethal cardiac arrhythmias. The importance of this cardiac phenotype in PDE4D-deficient mice is underscored by the fact that it is similar to that observed in humans with heart failure: decreased cardiac function and increased susceptibility to cardiac arrhythmias. Moreover, PDE inhibition has been associated with increased mortality in patients with heart failure (Packer et al., 1991) Since the PDE4D deficiency caused no detectable alteration in global cAMP levels or β-adrenergic signaling in the heart, the cardiac phenotype in PDE4D −/− mice must be due to abnormalities in localized signaling, i.e., altered microdomains of cAMP, which is supported by our FRET imaging data showing increased cAMP concentrations at the Z lines of PDE4D-deficient cardiomyocytes (where RyR2 is present) after physiologic stimulation of β-adrenergic receptors. Indeed, the concept that localized signaling regulates cAMP in the heart is supported by previous findings showing that PDE4 is a localized regulator of β-adrenergic receptor (Figure 3) , is a critical event since crossing the PDE4D-deficient mice with RyR2-S2808A mice inhibits the development of the cardiac phenotype (Figures 6 and 7) .
Indeed, there are at least two lines of evidence that strongly suggest that the cardiac phenotype in PDE4D-deficient mice is due to defects related to PKA hyperphosphorylation of RyR2 and the resulting abnormal regulation of this channel required for EC coupling in the heart. First, the levels of PDE4D3 in RyR2-channel complexes from failing human hearts are reduced to the same degree as in RyR2 complexes in the hearts of PDE4D +/− mice, which develop accelerated heart failure following myocardial infarction. This suggests that PDE4D deficiency in the RyR2 complex may play a role in PKA hyperphosphorylation of the channel and the associated cardiomyopathy. Second, and more importantly, sustained cardiac arrhythmias associated with pharmacologic PDE4 inhibition and accelerated progression of heart failure following MI were not observed in RyR2-S2808A mice harboring a RyR2 that cannot be PKA phosphorylated (Figures 6 and 7) . Thus, the present study indicates that the cardiac phenotype in PDE4D-deficient mice is directly related to defective regulation of RyR2 and provides support for the model whereby PKA hyperphosphorylation of RyR2 causes a diastolic SR Ca 2+ leak that (1) depletes SR Ca 2+ , contributing to decreased cardiac function (Marx et al., 2000) , and (2) may provide a trigger for fatal cardiac arrhythmias (Wehrens et al., 2003) .
Since the role of PKA hyperphosphorylation of RyR2 in heart failure (Jiang et al., 2002) has been challenged, it is important to establish a mechanism underlying the PKA hyperphosphorylation of RyR2 and to show that this defect can specifically account for the observed cardiac phenotype. We now show that PDE4D3 deficiency in the RyR2 complex contributes to PKA hyperphosphorylation of RyR2 in human and animal heart failure. Furthermore, a mutant RyR2 that cannot be PKA phosphorylated (RyR2-S2808A) protects against the cardiac effects of PDE4D3 deficiency in the RyR2 complex in vivo. Indeed, the finding that PDE4D3 is decreased in RyR2 complexes in human heart failure helps address one of the controversial issues in this field, the mechanism whereby RyR2 become PKA hyperphosphorylated (Marx et al., 2000) despite decreases in global cAMP levels in failing human hearts (RegitzZagrosek et al., 1994).
The current findings suggest a novel function of PDE4D3 in the regulation of RyR2, the major intracellular Ca 2+ -release channel in the heart. PDE4D3 activity provides an important negative-feedback mechanism to limit β-AR-dependent PKA phosphorylation of RyR2-Ser2808. Under physiologic conditions, PDE4D3 may regulate local PKA activity and channel activation via phosphorylation of RyR2-Ser2808, thereby preventing excess accumulation of cAMP (Zaccolo and Pozzan, 2002) and uncontrolled PKA-mediated activation of the channel. In human heart failure, loss of negative feedback due to PDE4D3 deficiency in the RyR2 complex likely contributes to RyR2 PKA hyperphosphorylation; calstabin2 depletion; and hyperactive, "leaky" RyR2 channels (Marx et al., 2000; Pieske et al., 1999) . Taken together, our data suggest that PDE4D3 plays a protective role in the heart against heart failure and arrhythmias.
These data further suggest that chronic pharmacologic PDE4 inhibition could contribute to a cardiac phenotype including cardiac dysfunction and arrhythmias, particularly in individuals with underlying cardiac disease. In addition, other signaling systems may be affected by reduced PDE4D activity, e.g., β-arrestin targeting of PDE4D3 activity may be important for β2-AR desensitization (Perry et al., 2002) . Importantly, PDE4D3 deficiency and pharmacologic PDE4 inhibition with rolipram was associated with stress-induced cardiac arrhythmias, which did not occur in mice lacking the RyR2 PKA phosphorylation site at Ser2808. These findings suggest that PDE4 inhibitors could increase the risk of cardiac arrhythmias due to "leaky" RyR2 channels as observed in individuals with genetic forms of sudden cardiac death linked to RyR2 mutations (Lehnart et al., 2004; Wehrens et al., 2003) and in patients with heart failure.
Experimental Procedures
PDE4D
-/-Mice and RyR2-S2808A Knockin Mice PDE4D -/-mice were generated and genotyped as described (Jin et al., 1999) . RyR2-S2808A knockin mice (see the Supplemental Data available with this article online for details), generated using homologous recombination, exhibited normal cardiac structure and function, and no PKA phosphorylation of RyR2 was detected using a kinasing reaction with [γ- 
Myocardial Infarct Model
PDE4D
-/-and age-and-litter-matched wild-type mice (4 to 5 months old) were anesthetized with 1.5% isoflurane and ventilated with a small-rodent respirator (Harvard Apparatus). A left thoracotomy was performed, and the left anterior descending artery (LAD) was ligated proximally with an 8-0 suture as described (Wehrens et al., 2005) .
Exercise Testing and Mouse ECG Recording
Ambulatory ECG recordings were performed using implantable radiotelemetry transmitters (DSI) as described (Wehrens et al., 2004) . For the pharmacological experiments performed in wt and RyR2-S2808A knockin mice, animals were pretreated for 30 min by intraperitoneal injection with the PDE4 inhibitor rolipram (0.3 mg/kg) or placebo (DMSO 0.5% as carrier) followed by the exercise protocol described above. 
␤-Adrenergic-Receptor
Back Phosphorylation of PDE4D3
PKA phosphorylation of PDE4D3 was assessed using a kinasing reaction on PDE4D3 immunoprecipitated from 100 g of human cardiac homogenates (see Supplemental Data for details). 
Single-Channel Recordings
Statistical Analysis
Data are reported as mean ± SEM for in vivo experiments and mean ± SD for biochemical studies. Differences between multiple experimental groups were compared by analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Analysis between two groups was performed by t test (paired or unpaired as appropriate). Serial studies were tested by repeated-measure ANOVA. A value of p < 0.05 was considered significant. 
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